

HÃ©lÃ¨ne Hanaire

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6604159/publications.pdf>

Version: 2024-02-01

18
papers

1,080
citations

687220

13
h-index

887953

17
g-index

19
all docs

19
docs citations

19
times ranked

1229
citing authors

#	ARTICLE	IF	CITATIONS
1	Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial. <i>Diabetes Therapy</i> , 2017, 8, 55-73.	1.2	433
2	Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial. <i>The Lancet Digital Health</i> , 2019, 1, e17-e25.	5.9	146
3	Use of Flash Glucose-Sensing Technology for 12 Months as a Replacement for Blood Glucose Monitoring in Insulin-treated Type 2 Diabetes. <i>Diabetes Therapy</i> , 2017, 8, 573-586.	1.2	141
4	Assessment of Patient-Led or Physician-Driven Continuous Glucose Monitoring in Patients With Poorly Controlled Type 1 Diabetes Using Basal-Bolus Insulin Regimens. <i>Diabetes Care</i> , 2012, 35, 965-971.	4.3	85
5	High Glycemic Variability Assessed by Continuous Glucose Monitoring After Surgical Treatment of Obesity by Gastric Bypass. <i>Diabetes Technology and Therapeutics</i> , 2011, 13, 625-630.	2.4	57
6	Practical implementation, education and interpretation guidelines for continuous glucose monitoring: A French position statement. <i>Diabetes and Metabolism</i> , 2018, 44, 61-72.	1.4	53
7	Efficacy of the Diabeloop closed-loop system to improve glycaemic control in patients with type 1 diabetes exposed to gastronomic dinners or to sustained physical exercise. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 324-334.	2.2	30
8	Preliminary Evaluation of a New Semi-Closed-Loop Insulin Therapy System Over the Prandial Period in Adult Patients With Type 1 Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2014, 8, 1177-1184.	1.3	20
9	Practical implementation of automated closed-loop insulin delivery: A French position statement. <i>Diabetes and Metabolism</i> , 2021, 47, 101206.	1.4	19
10	DIABEO System Combining a Mobile App Software With and Without Telemonitoring Versus Standard Care: A Randomized Controlled Trial in Diabetes Patients Poorly Controlled with a Basal-Bolus Insulin Regimen. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 904-911.	2.4	18
11	External insulin pump treatment in the day-to-day management of diabetes: benefits and future perspectives. <i>Diabetes and Metabolism</i> , 2011, 37, S40-S47.	1.4	16
12	Remote Monitoring of Diabetes: A Cloud-Connected Digital System for Individuals With Diabetes and Their Health Care Providers. <i>Journal of Diabetes Science and Technology</i> , 2019, 13, 1161-1168.	1.3	15
13	Obstructive sleep apnoea syndrome in patients living with diabetes: Which patients should be screened?. <i>Diabetes and Metabolism</i> , 2019, 45, 91-101.	1.4	15
14	DIABEO App Software and Telemedicine Versus Usual Follow-Up in the Treatment of Diabetic Patients: Protocol for the TELESAGE Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2018, 7, e66.	0.5	13
15	No more hypoglycaemia on days with physical activity and unrestricted diet when using a closed-loop system for 12 weeks: A post hoc secondary analysis of the multicentre, randomized controlled Diabeloop WP7 trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2170-2176.	2.2	11
16	Reduction of clinically important low glucose excursions with a long-term implantable continuous glucose monitoring system in adults with type 1 diabetes prone to hypoglycaemia: the France Adoption Randomized Clinical Trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 859-867.	2.2	6
17	Characteristics of pregnant women with diabetes using injectable glucose-lowering drugs in the EVOLVE study. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2022, 35, 7992-8000.	0.7	2
18	Design of a prospective, longitudinal cohort of people living with type 1 diabetes exploring factors associated with the residual cardiovascular risk and other diabetes-related complications: the SFDT1 study. <i>Diabetes and Metabolism</i> , 2021, 48, 101306.	1.4	0